Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
1.36
Nov 06 • 3:58 PM ET Dollar change+0.06 Percentage change(4.62%)
Aftermarket Close
1.37
Aftermarket • 7:54 PM ET Dollar change+0.01 Percentage change(0.74%)
Index
-
Market Cap
9.29M
Enterprise Value
-0.13M
Income
-21.24M
Sales
0.00M
Book/sh
0.90
Cash/sh
2.73
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
16
IPO
Sep 25, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.52
P/C
0.50
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
5.58
Current Ratio
5.58
Debt/Eq
1.67
LT Debt/Eq
1.67
Option/Short
No / Yes
EPS (ttm)
-6.79
EPS next Y
-5.30
EPS next Q
-1.27
EPS this Y
69.37%
EPS next Y
-75.69%
EPS next 5Y
36.90%
EPS past 3/5Y
89.18% 38.92%
Sales past 3/5Y
- -
EPS Y/Y TTM
15.38%
Sales Y/Y TTM
-
EPS Q/Q
-12.66%
Sales Q/Q
-
Insider Own
39.39%
Insider Trans
10.20%
Inst Own
34.19%
Inst Trans
22.62%
ROA
-110.10%
ROE
-365.70%
ROIC
-144.36%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
6.73%
SMA50
-15.98%
SMA200
-59.86%
Trades
Shs Outstand
6.15M
Shs Float
4.14M
52W High
36.00 -96.22%
52W Low
1.00 36.00%
Volatility
15.50% 14.52%
ATR (14)
0.19
RSI (14)
46.15
Beta
0.80
Rel Volume
0.25
Avg Volume
81.29K
Volume
20,569
Perf Week
-6.85%
Perf Month
4.62%
Perf Quarter
-58.73%
Perf Half Y
-56.76%
Perf YTD
-95.87%
Perf Year
-91.11%
Perf 3Y
-91.50%
Perf 5Y
-99.40%
Perf 10Y
-
Prev Close
1.30
Price
1.36
Change %
4.62%
Consensus
Buy
Avg. Price Target
$37.50
Implied Upside
+2,657.4%
Analysts2incl. previous ratings
Rating Distribution1 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 20, 2026Initiated
GGuggenheim
Buy$9+561.8%
Jan 29, 2026Downgrade
HH.C. Wainwright
Buy → Neutral
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Middleton Fred ADirectorJun 25 '26Buy0.80248,972199,9991,063,272Jun 29 08:45 AM
CalciMedica, Inc. is a clinical-stage biopharmaceutical company, which engages in developing therapies for life-threatening inflammatory diseases. The firm's product candidate, Auxora, helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.
CEO & DirectorDr. A. Rachel Leheny Ph.D.
Chief Business Officer & Vice Chairman of the BoardMr. Eric W. Roberts
Chief Medical OfficerDr. Sudarshan Hebbar M.D.
M.B.A.Mr. Michael J. Dunn B.A.
Co-Founder and Scientific AdvisorDr. Anjana Rao Ph.D.